Proliferation and differentiation of human osteoblasts from a type 2 diabetic patient in vitro

Li, J.; Liu, C.Y.; Jiang, Ying; Wei, Xiaoyi; Li, J.U.

doi:10.4238/2015.september.22.23

Cited by 9 publications

(12 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, our previous study revealed that the migration, proliferation, and osteogenic differentiation ability of BMSCs derived from the jawbone marrow of T2DM patients (DM-BMSCs) was significantly diminished compared to the BMSCs from normal controls (N-BMSCs). 9 , 10 Therefore, enhancing the function of DM-BMSCs and improving the implant success rate are critical for implant surgery.…”

Section: Introductionmentioning

confidence: 99%

Specific RNA m6A modification sites in bone marrow mesenchymal stem cells from the jawbone marrow of type 2 diabetes patients with dental implant failure

et al. 2023

View full text Add to dashboard Cite

The failure rate of dental implantation in patients with well-controlled type 2 diabetes mellitus (T2DM) is higher than that in non-diabetic patients. This due, in part, to the impaired function of bone marrow mesenchymal stem cells (BMSCs) from the jawbone marrow of T2DM patients (DM-BMSCs), limiting implant osseointegration. RNA N6-methyladenine (m6A) is important for BMSC function and diabetes regulation. However, it remains unclear how to best regulate m6A modifications in DM-BMSCs to enhance function. Based on the “m6A site methylation stoichiometry” of m6A single nucleotide arrays, we identified 834 differential m6A-methylated genes in DM-BMSCs compared with normal-BMSCs (N-BMSCs), including 43 and 790 m6A hypermethylated and hypomethylated genes, respectively, and 1 gene containing hyper- and hypomethylated m6A sites. Differential m6A hypermethylated sites were primarily distributed in the coding sequence, while hypomethylated sites were mainly in the 3′-untranslated region. The largest and smallest proportions of m6A-methylated genes were on chromosome 1 and 21, respectively. MazF-PCR and real-time RT-PCR results for the validation of erythrocyte membrane protein band 4.1 like 3, activity-dependent neuroprotector homeobox (ADNP), growth differentiation factor 11 (GDF11), and regulator of G protein signalling 2 agree with m6A single nucleotide array results; ADNP and GDF11 mRNA expression decreased in DM-BMSCs. Furthermore, gene ontology and Kyoto Encyclopedia of Genes and Genomes analyses suggested that most of these genes were enriched in metabolic processes. This study reveals the differential m6A sites of DM-BMSCs compared with N-BMSCs and identifies candidate target genes to enhance BMSC function and improve implantation success in T2DM patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Specific RNA m6A modification sites in bone marrow mesenchymal stem cells from the jawbone marrow of type 2 diabetes patients with dental implant failure

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Bone marrow mesenchymal stem cells (BMSCs) play an important role in the process of osseointegration of oral implants by modulating cell proliferation, adhesion and osteogenic differentiation to regulate the remodelling of bone tissue around newly introduced implants (Biguetti et al, 2018; Huo & Yue, 2020; Martínez‐Ibáñez et al, 2018). Jawbone marrow mesenchymal stem cells (JBMSCs) from patients with T2DM exhibit significantly lower proliferation, migration, differentiation and mineralisation activities than cells derived from patients without T2DM (Li et al, 2015). Therefore, the reduced osteogenic differentiation potential of JBMSCs in T2DM patients could be responsible for the failure of osseointegration.…”

Section: Introductionmentioning

confidence: 99%

microRNA‐491‐5p regulates osteogenic differentiation of bone marrow stem cells in type 2 diabetes

et al. 2021

View full text Add to dashboard Cite

Objectives Osseointegration of oral implants has a low success rate in patients with type 2 diabetes. This is because of the inhibition of osteogenic differentiation in the jawbone marrow mesenchymal stem cells, in which the expression of microRNA(miR)‐491‐5p is significantly downregulated, as ascertained through gene chip screening. However, the underlying mechanisms are unclear. Here, we aimed to clarify the mechanisms involved in the influence of miR‐491‐5p on osteogenic differentiation. Subjects and methods: Jawbone marrow mesenchymal stem cells were isolated from jawbones of patients with type 2 diabetes and subjected to bioinformatics and functional analyses. Osteogenesis experiments were conducted using the isolated cells and an in vivo model. Results Knockdown and overexpression experiments revealed the positive effects of miR‐491‐5p expression on osteogenic differentiation in vivo and in vitro. Additionally, a dual‐luciferase assay revealed that miR‐491‐5p targeted the SMAD/RUNX2 pathway by inhibiting the expression of epidermal growth factor receptor. Conclusions miR‐491‐5p is vital in osteogenic differentiation of jawbone mesenchymal stem cells; its downregulation in type 2 diabetes could be a major cause of decreased osteogenic differentiation. Regulation of miR‐491‐5p expression could improve osteogenic differentiation of jawbone mesenchymal stem cells in patients with type 2 diabetes.

show abstract

“…After the BMSCs adhere to the implant surface, the osteogenic differentiation process is initiated, and new bone gradually forms with the assistance of cells, blood, and related cytokines [7]. Previous studies have shown that BMSC proliferation, migration, differentiation, and mineralization in T2DM patients are significantly inferior to those in nondiabetic patients [8]. The weakened osteogenic differentiation potential of BMSCs in T2DM patients might be an important reason for the failure of implant osseointegration at the healing stage.…”

Section: Introductionmentioning

confidence: 99%

Effect of the Abnormal Expression of BMP-4 in the Blood of Diabetic Patients on the Osteogenic Differentiation Potential of Alveolar BMSCs and the Rescue Effect of Metformin: A Bioinformatics-Based Study

Liang

Sun

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

The success rate of oral implants is lower in type 2 diabetes mellitus (T2DM) patients than in nondiabetic subjects; functional impairment of bone marrow-derived mesenchymal stem cells (BMSCs) is an important underlying cause. Many factors in the blood can act on BMSCs to regulate their biological functions and influence implant osseointegration, but which factors play important negative roles in T2DM patients is still unclear. This study is aimed at screening differentially expressed genes in the blood from T2DM and nondiabetic patients, identifying which genes impact the osteogenic differentiation potential of alveolar BMSCs in T2DM patients, exploring drug intervention regimens, and providing a basis for improving implant osseointegration. Thus, a whole-blood gene expression microarray dataset (GSE26168) of T2DM patients and nondiabetic controls was analyzed. Based on Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) results, differentially expressed genes and signaling pathways related to BMSC osteogenic differentiation were screened, and major risk genes were extracted based on the mean decrease Gini coefficient calculated using the random forest method. Bone morphogenetic protein-4 (BMP-4), with significantly low expression in T2DM blood, was identified as the most significant factor affecting BMSC osteogenic differentiation potential. Subsequently, metformin, a first-line clinical drug for T2DM treatment, was found to improve the osteogenic differentiation potential of BMSCs from T2DM patients via the BMP-4/Smad/Runx2 signaling pathway. These results demonstrate that low BMP-4 expression in the blood of T2DM patients significantly hinders the osteogenic function of BMSCs and that metformin is effective in counteracting the negative impact of BMP-4 deficiency.

show abstract

Proliferation and differentiation of human osteoblasts from a type 2 diabetic patient in vitro

Cited by 9 publications

References 19 publications

Specific RNA m6A modification sites in bone marrow mesenchymal stem cells from the jawbone marrow of type 2 diabetes patients with dental implant failure

Specific RNA m6A modification sites in bone marrow mesenchymal stem cells from the jawbone marrow of type 2 diabetes patients with dental implant failure

microRNA‐491‐5p regulates osteogenic differentiation of bone marrow stem cells in type 2 diabetes

Effect of the Abnormal Expression of BMP-4 in the Blood of Diabetic Patients on the Osteogenic Differentiation Potential of Alveolar BMSCs and the Rescue Effect of Metformin: A Bioinformatics-Based Study

Contact Info

Product

Resources

About